| KOLAROVA, Iveta, Ladislav DUŠEK, Ales RYSKA, Karel ODRAZKA, Martin DOLEZEL, Jaroslav VANASEK, Bohuslav MELICHAR, Jiri PETERA, Tomas BUCHLER, Milan VOSMIK, Katarina PETRAKOVA, Petra TERAROVA, Zdena VILASOVA and Jiří JARKOVSKÝ. Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2020, vol. 34, No 6, p. 3441-3449. ISSN 0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12183. |
Other formats:
BibTeX
LaTeX
RIS
@article{1703238,
author = {Kolarova, Iveta and Dušek, Ladislav and Ryska, Ales and Odrazka, Karel and Dolezel, Martin and Vanasek, Jaroslav and Melichar, Bohuslav and Petera, Jiri and Buchler, Tomas and Vosmik, Milan and Petrakova, Katarina and Terarova, Petra and Vilasova, Zdena and Jarkovský, Jiří},
article_location = {ATHENS},
article_number = {6},
doi = {http://dx.doi.org/10.21873/invivo.12183},
keywords = {Breast cancer; triple positive; HER2-positive; hormone receptors; overall survival; trastuzumab},
language = {eng},
issn = {0258-851X},
journal = {In vivo},
title = {Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer},
url = {http://iv.iiarjournals.org/content/34/6/3441.full.pdf},
volume = {34},
year = {2020}
}
TY - JOUR
ID - 1703238
AU - Kolarova, Iveta - Dušek, Ladislav - Ryska, Ales - Odrazka, Karel - Dolezel, Martin - Vanasek, Jaroslav - Melichar, Bohuslav - Petera, Jiri - Buchler, Tomas - Vosmik, Milan - Petrakova, Katarina - Terarova, Petra - Vilasova, Zdena - Jarkovský, Jiří
PY - 2020
TI - Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer
JF - In vivo
VL - 34
IS - 6
SP - 3441-3449
EP - 3441-3449
PB - Greece : International Institute of Anticancer Research
SN - 0258851X
KW - Breast cancer
KW - triple positive
KW - HER2-positive
KW - hormone receptors
KW - overall survival
KW - trastuzumab
UR - http://iv.iiarjournals.org/content/34/6/3441.full.pdf
L2 - http://iv.iiarjournals.org/content/34/6/3441.full.pdf
N2 - Background/Aim: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. Patients and Methods: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. Results: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. Conclusion: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.
ER -
KOLAROVA, Iveta, Ladislav DUŠEK, Ales RYSKA, Karel ODRAZKA, Martin DOLEZEL, Jaroslav VANASEK, Bohuslav MELICHAR, Jiri PETERA, Tomas BUCHLER, Milan VOSMIK, Katarina PETRAKOVA, Petra TERAROVA, Zdena VILASOVA and Jiří JARKOVSKÝ. Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2020, vol.~34, No~6, p.~3441-3449. ISSN~0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12183.
|
